FHD-909

N/A

Report date: 2025/07/07 20:00:09

Base Information

Drug NameFHD-909
Drug Alias NameFHD-909LY4050784LY-4050784
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProbable global transcription activator SNF2L2 inhibitors
TargetsProbable global transcription activator SNF2L2
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsEndometrial Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyUnited Kingdom +[7] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFoghorn Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyFoghorn Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsEndometrial Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A